58 related articles for article (PubMed ID: 24445147)
1. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Meyer T; Qian W; Caplin ME; Armstrong G; Lao-Sirieix SH; Hardy R; Valle JW; Talbot DC; Cunningham D; Reed N; Shaw A; Navalkissoor S; Luong TV; Corrie PG
Eur J Cancer; 2014 Mar; 50(5):902-11. PubMed ID: 24445147
[TBL] [Abstract][Full Text] [Related]
2. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of streptozocin-based chemotherapy for gastroenteropancreatic neuroendocrine tumors in Japanese clinical practice.
Murakami M; Fujimori N; Takamatsu Y; Ito T; Matsumoto K; Kakehashi S; Ohno A; Teramatsu K; Ueda K; Ishigami K; Ogawa Y
Jpn J Clin Oncol; 2024 Jun; 54(6):647-657. PubMed ID: 38422348
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Al-Toubah T; Morse B; Pelle E; Strosberg J
Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478
[TBL] [Abstract][Full Text] [Related]
6. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
Park SH; Lee Y; Han SH; Kwon SY; Kwon OS; Kim SS; Kim JH; Park YH; Lee JN; Bang SM; Cho EK; Shin DB; Lee JH
BMC Cancer; 2006 Jan; 6():3. PubMed ID: 16396674
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study.
Jeong H; Shin J; Jeong JH; Kim KP; Hong SM; Kim YI; Ryu JS; Ryoo BY; Yoo C
ESMO Open; 2021 Jun; 6(3):100119. PubMed ID: 33901869
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
de Mestier L; Walter T; Evrard C; de Boissieu P; Hentic O; Cros J; Tougeron D; Lombard-Bohas C; Rebours V; Hammel P; Ruszniewski P
Neuroendocrinology; 2020; 110(1-2):83-91. PubMed ID: 31071715
[TBL] [Abstract][Full Text] [Related]
9. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
15. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.
Dobson R; Burgess MI; Valle JW; Pritchard DM; Vora J; Wong C; Chadwick C; Keevi B; Adaway J; Hofmann U; Poston GJ; Cuthbertson DJ
Br J Cancer; 2014 Oct; 111(9):1703-9. PubMed ID: 25211656
[TBL] [Abstract][Full Text] [Related]
16. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
17. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.
Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
[TBL] [Abstract][Full Text] [Related]
19. Smoking and survival of colorectal cancer patients: systematic review and meta-analysis.
Walter V; Jansen L; Hoffmeister M; Brenner H
Ann Oncol; 2014 Aug; 25(8):1517-25. PubMed ID: 24692581
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
